Fulcrum Therapeutics™ to Participate in Upcoming November Investor Conferences
Fulcrum Therapeutics (Nasdaq: FULC) announced management participation in key investor conferences.
Sentiment and the balance of points
Rhea-AI Sentiment reads the wording of the document, how positive or negative its language is on a 1 to 5 scale. The balance of points shown with the takes weighs what the document actually discloses, so the two can disagree, for example when a trial that missed its main goal is described in upbeat language.
Rhea-AI Summary
Fulcrum Therapeutics (Nasdaq: FULC) announced management participation in key investor conferences. These include the Credit Suisse 30th Annual Virtual Healthcare Conference on November 11, 2021 at 4:20pm ET, the Stifel Virtual Healthcare Conference on November 17, 2021 at 11:20am ET, and the Piper Sandler 33rd Annual Virtual Healthcare Conference on November 30, 2021. Live audio webcasts will be accessible via the Investor Relations section of the Fulcrum website, with archived replays available for 30 days.
Details
News Market Reaction – FULC
The recorded move for FULC in the trading session of this news was -1.92%.
Data tracked by StockTitan Argus. Session date unavailable.
AI-generated analysis. How Rhea-AI works. Not financial advice.
CAMBRIDGE, Mass., Nov. 03, 2021 (GLOBE NEWSWIRE) -- Fulcrum Therapeutics, Inc. (Nasdaq: FULC), a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases, today announced that management will be participating in the following upcoming investor conferences:
- Credit Suisse 30th Annual Virtual Healthcare Conference
Thursday, November 11, 2021 at 4:20pm ET
- Stifel Virtual Healthcare Conference
Wednesday, November 17, 2021 at 11:20am ET
- Piper Sandler 33rd Annual Virtual Healthcare Conference
Tuesday, November 30, 2021. Webcast available beginning Monday, November 22, 2021 at 10:00am ET
Live audio webcasts will be available through the Investor Relations section of the Fulcrum website at https://ir.fulcrumtx.com/events-and-presentations. Archived replays will be available on the Company’s website for 30 days.
About Fulcrum Therapeutics
Fulcrum Therapeutics is a clinical-stage biopharmaceutical company focused on improving the lives of patients with genetically defined rare diseases in areas of high unmet medical need. Fulcrum’s proprietary product engine, FulcrumSeek™, identifies drug targets which can modulate gene expression to treat the known root cause of gene mis-expression. Fulcrum has advanced losmapimod to Phase 2 clinical development for the treatment of facioscapulohumeral muscular dystrophy (FSHD). Fulcrum has also advanced FTX-6058, a small molecule designed to increase expression of fetal hemoglobin for the treatment of sickle cell disease and beta-thalassemia into Phase 1 clinical development.
Please visit www.fulcrumtx.com.
Contact:
Naomi Aoki
Sr. Vice President, Corporate Communications
and Investor Relations
naoki@fulcrumtx.com
FAQ
AI-generated questions and answers. How Rhea-AI works. Not financial advice.